open access

Vol 64, No 4 (2014)
Review paper
Published online: 2014-09-01
Get Citation

Evaluation of response to treatment — criteria RECIST 1.1

Adam Płużański
DOI: 10.5603/NJO.2014.0055
·
Nowotwory. Journal of Oncology 2014;64(4):331-335.

open access

Vol 64, No 4 (2014)
Review article
Published online: 2014-09-01

Abstract

The assessment of objective response is important to the able to evaluated treatment outcome. Since its introduction in 2000, RECIST has been widely accepted to standardize the measurement of tumour response in clinical trials. The revised version 1.1 of RECIST is the currently recommended method of tumour response assessment in clinical trialsand in routine practice. Major changes in version 1.1 include: reduction of the number of target lesions, lymph node measurement of the nodal short axis, revised definition of progressive disease and implementation the new methods of tumour assessment. The objective of this article is to review the practical aspects of the new RECIST guideline version 1.1.

Abstract

The assessment of objective response is important to the able to evaluated treatment outcome. Since its introduction in 2000, RECIST has been widely accepted to standardize the measurement of tumour response in clinical trials. The revised version 1.1 of RECIST is the currently recommended method of tumour response assessment in clinical trialsand in routine practice. Major changes in version 1.1 include: reduction of the number of target lesions, lymph node measurement of the nodal short axis, revised definition of progressive disease and implementation the new methods of tumour assessment. The objective of this article is to review the practical aspects of the new RECIST guideline version 1.1.
Get Citation
About this article
Title

Evaluation of response to treatment — criteria RECIST 1.1

Journal

Nowotwory. Journal of Oncology

Issue

Vol 64, No 4 (2014)

Article type

Review paper

Pages

331-335

Published online

2014-09-01

DOI

10.5603/NJO.2014.0055

Bibliographic record

Nowotwory. Journal of Oncology 2014;64(4):331-335.

Authors

Adam Płużański

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl